This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Stocks Yahoo Finance By Yahoo Finance 02 Jun 2026 16:13 1 min read

This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance.